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ABSTRACT Flaviviruses are a diverse group of arthropod-borne viruses responsible
for numerous significant public health threats; therefore, understanding the interac-
tions between these viruses and the human immune response remains vital. West
Nile virus (WNV) and Zika virus (ZIKV) infect human dendritic cells (DCs) and can
block antiviral immune responses in DCs. Previously, we used mRNA sequencing and
weighted gene coexpression network analysis (WGCNA) to define molecular signa-
tures of antiviral DC responses following activation of innate immune signaling
(RIG-I, MDA5, or type I interferon [IFN] signaling) or infection with WNV. Using
this approach, we found that several genes involved in T cell cosignaling and an-
tigen processing were not enriched in DCs during WNV infection. Using cis-
regulatory sequence analysis, STAT5 was identified as a regulator of DC activa-
tion and immune responses downstream of innate immune signaling that was
not activated during either WNV or ZIKV infection. Mechanistically, WNV and
ZIKV actively blocked STAT5 phosphorylation downstream of RIG-I, IFN-, and
interleukin-4 (IL-4), but not granulocyte-macrophage colony-stimulating factor
(GM-CSF), signaling. Unexpectedly, dengue virus serotypes 1 to 4 (DENV1 to
DENV4) and the yellow fever 17D vaccine strain (YFV-17D) did not antagonize STAT5
phosphorylation. In contrast to WNV, ZIKV inhibited JAK1 and TYK2 phosphorylation
following type I IFN treatment, suggesting divergent mechanisms used by these vi-
ruses to inhibit STAT5 activation. Combined, these findings identify STAT5 as a tar-
get of antagonism by specific pathogenic flaviviruses to subvert the immune re-
sponse in infected DCs.
IMPORTANCE Flaviviruses are a diverse group of insect-borne viruses responsible for
numerous significant public health threats. Previously, we used a computational biol-
ogy approach to define molecular signatures of antiviral DC responses following ac-
tivation of innate immune signaling or infection with West Nile virus (WNV). In this
work, we identify STAT5 as a regulator of DC activation and antiviral immune re-
sponses downstream of innate immune signaling that was not activated during ei-
ther WNV or Zika virus (ZIKV) infection. WNV and ZIKV actively blocked STAT5 phos-
phorylation downstream of RIG-I, IFN-, and IL-4, but not GM-CSF, signaling.
However, other related flaviviruses, dengue virus serotypes 1 to 4 and the yellow fe-
ver 17D vaccine strain, did not antagonize STAT5 phosphorylation. Mechanistically,
WNV and ZIKV showed differential inhibition of Jak kinases upstream of STAT5, sug-
gesting divergent countermeasures to inhibit STAT5 activation. Combined, these
findings identify STAT5 as a target of antagonism by specific pathogenic flaviviruses
to subvert antiviral immune responses in human DCs.
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West Nile virus (WNV) is a neurotropic flavivirus, and it has been the leading causeof arboviral neuroinvasive disease since its introduction to the United States in
1999, accounting for 95% of reported cases (1). After inoculation by an infected
mosquito, 20 to 25% of WNV-infected individuals develop symptoms ranging from mild
flu-like symptoms to severe neurologic disease, including meningitis, encephalitis, and
acute flaccid paralysis (2). Longer-lasting sequelae of WNV-induced fever and neuroin-
vasive disease include ocular abnormalities, arthralgias, psychological impairment, and
permanent memory loss (3). Recently, WNV has also been shown in mice to translocate
across the placenta and infect fetal neuronal tissue during pregnancy, prompting fetal
demise (4). The lack of FDA-approved antiviral therapeutics or vaccines for human WNV
infection reinforces the need to further understand innate immune signaling during
WNV pathogenesis.
Dendritic cells (DCs) are vital components of both the innate and adaptive immune
responses during flavivirus infection. DCs are professional antigen-presenting cells that,
upon infection, can process and present antigens on major histocompatibility complex
(MHC) molecules, express costimulatory markers, and produce cytokines necessary for
activation of the adaptive immune response (5). Mouse models of WNV pathogenesis
have demonstrated that DCs are initial targets of infection by WNV and that innate
immune signaling in DCs is essential for clearance of neuroinvasive disease (6–9). In the
absence of type I interferon (IFN) signaling in murine DCs, WNV shows increased
replication in myeloid cells and enhanced tissue tropism, resulting in increased mor-
tality in mice (7). Adoptive transfer studies in mice have also demonstrated that
immunocompetent DCs are essential for proper priming of WNV-specific T cell re-
sponses and viral clearance from the central nervous system (8). Recent studies have
also established that WNV and a related neurotropic flavivirus, Zika virus (ZIKV),
productively infect human monocyte-derived dendritic cells (moDCs) and suppress
expression of costimulatory markers on infected DCs (10). WNV-infected DCs also
display a reduced capacity to induce allogeneic CD4 and CD8 T cell proliferation (11).
However, the exact mechanism of viral antagonism of human DC activation during
WNV infection remains unknown.
During infection in DCs, intracellular WNV RNA is detected by the RIG-I like receptors
(RLRs) RIG-I and MDA5, which interact with the adaptor protein mitochondrial antiviral
signaling (MAVS) to induce transcription of proinflammatory cytokines, antiviral effec-
tors, and type I IFN (12, 13). Upon release of type I IFN (IFN-/), this signal is further
potentiated through the type I IFN receptor (IFNAR), causing phosphorylation of bound
Janus kinases (JAKs) and subsequent signal transducer and activator of transcription
(STAT) proteins (14). Once phosphorylated, STAT proteins will dimerize and translocate
to the nucleus, bind to IFN-stimulated response elements (ISREs) on DNA, and initiate
robust induction of interferon-stimulated genes (ISGs) to restrict viral replication.
Canonically, IFNAR signals through STAT1 and STAT2 heterodimers, both of which are
targets of flavivirus antagonism to inhibit antiviral responses (10, 15–18).
In addition, IFNAR can signal through STAT5, a pleiotropic STAT protein activated
downstream of numerous cytokines and growth factors. STAT5 exists as two homologs,
STAT5a and STAT5b, which share 96% homology at the protein level and homodimerize
upon activation and bind gamma-activated sequence (GAS) elements on DNA (19).
STAT5 signaling plays a variety of roles involving DC development and activation.
Generation of conventional DCs requires STAT5 signaling by inhibition of plasmacytoid
DC development through induction of interferon regulatory factor 8 (IRF8) (20). Con-
ditional knockout mouse studies have also established that STAT5 signaling is essential
for thymic stromal lymphopoietin (TSLP)-induced activation of DCs and allergic Th2
responses in the lungs (21). Inhibition of STAT5 signaling in monocyte-derived dendritic
cells (moDCs) also inhibits lipopolysaccharide-induced DC maturation, costimulatory
marker expression, and stimulation of Th1 immune responses (22). Despite the role of
STAT5 in DC development and maturation, the importance of STAT5 signaling in DCs
during viral infection is currently unknown.
Here, we employed a coexpression network-based analysis combined with promoter
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scanning analysis, and we identified STAT5, a critical transcription factor for regulating 
antiviral responses and activation within human DCs, downstream of RLR and type I IFN 
signaling. WNV and ZIKV infection induced minimal STAT5 signaling, corresponding 
with a failure to upregulate innate immune mediators and molecules involved in DC 
activation. WNV and ZIKV antagonism of STAT5 in moDCs was also receptor specific, 
inhibiting type I IFN and interleukin-4 (IL-4), but not granulocyte-macrophage colony-
stimulating factor GM-CSF, and inducing STAT5 phosphorylation downstream of JAK 
kinase signaling. Surprisingly, WNV and ZIKV, but not dengue virus serotypes 1 to 4 
(DENV1 to DENV4) or yellow fever virus vaccine strain 17D (YFV-17D), blocked STAT5 
signaling in Vero cells with differential upstream blockade of JAK kinase signaling, 
suggesting that targeting STAT5 may be a virus-specific strategy of WNV and ZIKV to 
subvert antiviral responses.
RESULTS
STAT5 is a regulatory node of antiviral DC responses. Previous work from our lab 
utilized a systems biology approach to assess the global antiviral response during WNV 
infection within primary human monocyte-derived DCs. Using moDCs from 5 different 
donors, we performed mRNA sequencing (mRNA-seq) following treatment with innate 
immune agonists targeting the RIG-I, MDA5, and IFNAR signaling pathways as well as 
infection with WNV at 12 and 24 hpi, signifying log phase viral growth (11). Using 
weighted gene coexpression network analysis (WGCNA) and Metacore pathway anal-
ysis, we determined that innate immune agonist treatments and WNV infection at 24 
hpi induced notable gene expression within module 5 (M5), a subset of differentially 
expressed genes (DEGs) highly enriched for pathways involved in type I IFN signaling, 
pattern recognition receptor (PRR) signaling, and innate antiviral responses. WGCNA 
clusters DEGs into modules based on coexpression, suggesting the presence of com-
mon transcriptional regulators driving gene expression within a module. To define the 
transcriptional regulatory network of the M5 antiviral module, we performed cis-
regulatory sequence analysis to computationally predict regulatory nodes using iRegu-
lon, which identifies enrichment of transcription factor binding motifs within the top 
highly connected genes comprising M5 (24). Consistent with pathway enrichment for 
antiviral pathways, our analysis identified the ISGF3 transcription complex, IRF1, and 
NF-B within the top predicted transcriptional regulators of M5 following RIG-I stimu-
lation. Unexpectedly, we also found notable enrichment for STAT5, a transcriptional 
regulator with a previously described role in promoting DC activation (21, 22) (Fig. 1A).
STAT5 regulates expression of genes associated with innate immunity and DC 
activation. Given that a role for STAT5 has not been previously implicated during 
flavivirus infection, we next evaluated the expression levels of predicted STAT5 target 
genes. Predicted STAT5 target genes included multiple genes associated with innate 
immunity (e.g., IRF1, Toll-like receptor 7 [TLR7], and TRIM25) and DC activation (e.g., 
CD80, CXCL11, and CCL2) (Fig. 1B). RIG-I agonist treatment induced upregulation of 
predicted STAT5 target genes. Treatment with transfected poly(I·C) and type I IFN also 
activated transcription of several STAT5 target genes although to a lesser extent than 
RIG-I agonist treatment. Given recent work implicating STAT5 signaling upstream of DC 
activation, in part through binding to the promoter regions of CD80 and CD83, we 
hypothesized that STAT5 might be an important regulator of DC activation downstream 
of RLR signaling (21, 22). Indeed, multiple predicted STAT5 target genes were involved 
in processes related to DC activation, including molecules involved in T cell cosignaling 
(e.g., CD80, IDO1, and SLAMF1) and cytokine signaling (e.g., CCL2, CCL13, CXCL11, IL2RA, 
JAK2, SOCS, and CISH) (Fig. 1C). Treatment with RIG-I or MDA5 agonist induced 
significant upregulation of STAT5 targets involved in DC activation, corresponding with 
dose-dependent phosphorylation of STAT5 at tyrosine residue 694, a critical event for 
STAT5 dimerization and DNA binding (25). Notably, STAT5 phosphorylation coincided 
with the kinetics and magnitude of IRF3 phosphorylation (Fig. 1D and E). IFN- 
signaling also promoted STAT5 phosphorylation, confirming previous work describing
FIG 1 Systems biology reveals STAT5 as a regulatory node of antiviral DC responses. (A) Transcription factor regulatory network of module 5 gene expression
as predicted by iRegulon (left panel). The top predicted transcriptional regulators (yellow nodes) are shown with a connecting line to predicted target genes
(Continued on next page)
(orange nodes). The consensus sequence for promoter regions targeted by STAT5 as generated by iRegulon and annotated as transfac_public-M00459 (top
right panel) is shown. The number of predicted target genes and the normalized enrichment score (NES) for a given regulator are shown below (bottom
right panel). (B) The STAT5 regulatory node (center) is shown with the predicted target genes indicated (small nodes), as determined by iRegulon. (C) Heat
map of predicted STAT5 target genes after stimulation with innate immune agonists showing the log2 normalized fold change relative to the level in
uninfected, untreated cells is shown (2-fold change; significance, P  0.01). Genes that did not reach the significance threshold are depicted in black. Each
column within a treatment condition is marked by a unique color and represents a different donor (n  5 donors). (D) moDCs were treated with RIG-I agonist
(10 or 100 ng/1e6 cells) for 90 min or 18 h. (E) moDCs were treated with RIG-I or MDA5 agonist for 90 min (10, 100, 1,000, and 10,000 ng/1e6 cells). (F) moDCs
were treated with IFN- (1,000 IU/ml) for 30 min. For panels D to F, Western blot analysis was performed for the indicated proteins. Western blots are
representative of data obtained from 3 to 8 donors.
the activation of STAT5 by type I IFN signaling in other cell types (Fig. 1F) (26–28). 
Collectively, cis-regulatory analysis revealed STAT5 as a transcriptional regulator of 
numerous antiviral genes within human moDCs and implicates STAT5 as a regulator of 
DC responses downstream of the RLR and type I IFN signaling axes.
WNV and ZIKV actively antagonize STAT5 activation. In contrast to RLR and type 
I IFN stimulation, STAT5 signaling was substantially less enriched during WNV infection, 
where almost 80% of predicted STAT5 target genes, including those involved in DC 
activation, were not significantly expressed over levels in mock-infected cells (Fig. 2A). 
The minimal induction of STAT5 target genes corresponded to a lack of STAT5 phos-
phorylation following WNV infection during (24 hpi; 53.3% E protein-positive [protein] 
cells) and after (48 hpi) log phase viral growth, despite increased amounts of STAT5 
total protein by 48 hpi (Fig. 2B to D). Given that WNV infection induces type I IFN 
secretion at 48 hpi (11) and the selective lack of STAT5 phosphorylation during WNV 
infection of moDCs, we hypothesized that WNV antagonizes type I IFN-mediated STAT5 
signaling. Indeed, WNV infection potently blocked STAT5 phosphorylation following 
both RIG-I stimulation and IFN- treatment at 24 and 48 hpi (Fig. 2C and D). Infection 
with UV-inactivated WNV (UV-WNV) failed to block RIG-I-induced STAT5 phosphoryla-
tion, suggesting that viral replication is required for inhibition of STAT5 signaling. In 
notable contrast to STAT5, both STAT1 and STAT2 were phosphorylated during WNV 
infection, suggesting that STAT5 may be differentially modulated by WNV. ZIKV, a 
closely related neurotropic flavivirus that productively infects human moDCs (10), also 
antagonized STAT5 phosphorylation downstream of RIG-I and type I IFN signaling 
despite relatively low levels of infection (14.7% E protein cells) (Fig. 2B and E). 
Combined, our data strongly suggest that STAT5 is a target of antagonism by both WNV 
and ZIKV in human moDCs.
WNV and ZIKV block STAT5 phosphorylation in a pathway-specific manner. 
Next, we asked if WNV and ZIKV blocked STAT5 activation downstream of additional 
cytokine signaling pathways. Common gamma-chain family cytokines, such as IL-4, as 
well as multiple growth factors, including GM-CSF, signal through their respective 
receptors to promote STAT5 phosphorylation (29, 30) (Fig. 3A). Similar to our findings 
with type I IFN signaling, WNV infection dampened IL-4-induced STAT5 phosphoryla-
tion in moDCs (Fig. 3B). In contrast, WNV failed to antagonize GM-CSF signaling, 
whereby the increased STAT5 protein induced during infection led to increased STAT5 
phosphorylation. ZIKV also potently inhibited IL-4-mediated, but not GM-CSF-mediated, 
STAT5 phosphorylation in human DCs (Fig. 3C). Together, our findings suggest that 
WNV blocks STAT5 phosphorylation to antagonize STAT5-dependent gene induction in 
human moDCs in a pathway-specific manner.
Blockade of STAT5 phosphorylation is flavivirus specific. Secretion of type I IFN 
by infected moDCs may initiate negative regulators that downregulate type I IFN 
signaling independent of viral antagonism of STAT proteins. To remove confounding 
interpretations inherent with IFN-competent cells, we employed a Vero cell model of 
WNV infection, which allows for synchronous infection of cells that lack endogenous 
type I IFN signaling. Infection of Vero cells with WNV did not induce phosphorylation 
of STAT1, STAT2, or STAT5, consistent with the lack of an endogenous type I IFN 
response. Similar to our studies in human moDCs, pulse treatment of WNV-infected 
Vero cells (MOI of 0.01; 61.5% viral E protein cells) with IFN- revealed a substantial
FIG 1 Legend (Continued)
FIG 2 WNV actively blocks STAT5 phosphorylation and expression of STAT5 target genes. (A) Heat map of predicted STAT5 
target genes after stimulation with RIG-I agonist or infection with WNV (12 and 24 hpi) showing the log2 normalized fold change 
relative to levels in uninfected, untreated cells is shown (2-fold change; significance, P  0.01). Genes that did not reach the 
significance threshold are depicted in black. Each column within a treatment condition is marked by a unique color and 
represents a different donor (n  5 donors). (B) Representative flow cytometry plot of viral E protein cells after infection in 
moDCs after WNV or ZIKV infection (24 or 48 h; MOI of 10, based on Vero cell titer). SSC-H, side scatter height. (C) moDCs were 
treated with RIG-I agonist (100 ng/1e6 cells) for 90 min following no infection (Mock), infection with UV-inactivated WNV (MOI 
of 10; UV), or infection with replication-competent WNV (MOI of 10; WNV). (D and E) Human moDCs were left uninfected (Mock) 
or infected with WNV or ZIKV (24 or 48 h; MOI of 10, based on Vero cell titer). Cells were left untreated or pulse treated with 
IFN- (1,000 IU/ml) for 30 min. Data in panel B are representative of results obtained from two independent experiments. Data 
shown in panels C and D are representative of results obtained from 3 to 8 donors.
FIG 3 WNV and ZIKV inhibit STAT5 phosphorylation (P) in a pathway-dependent manner. (A) Schematic 
of STAT signaling downstream of type I IFN, IL-4, and GM-CSF signaling. (B and C) moDCs were infected 
with WNV or ZIKV (MOI of 10, based on Vero cell titer) for 48 h and treated with IL-4 (10 ng/ml) for 30 min 
or with GM-CSF (10 ng/ml) for 30 min. For panels B and C, Western blot analysis was performed for the 
indicated proteins. Data are representative of results obtained from 3 to 8 donors.
blockade of STAT5 phosphorylation (Fig. 4A and B). STAT1 and STAT2 phosphorylations 
were also blocked, but in contrast to that of STAT5, the blockade of STAT1 and STAT2 
was less pronounced. Blockade of STAT5 phosphorylation paralleled the large increase 
seen in WNV RNA and infectious virus release between 18 and 24 hpi during log phase 
viral growth (11). Together, these data strongly suggest that antagonism of STAT5 is an 
active immune evasion mechanism in moDCs and not a bystander effect of endoge-
nous type I IFN signaling during WNV infection. We next asked whether STAT5 
antagonism was unique to neurotropic flaviviruses (WNV and ZIKV) or if this mechanism 
is conserved among other flaviviruses. We infected Vero cells with ZIKV PR-2015 at an 
MOI that achieved levels of infection comparable to those in our studies with WNV (Fig. 
4B). ZIKV antagonized STAT5 phosphorylation in a dose-dependent manner at higher 
MOIs (MOI of 1; 85% viral E protein cells) rather than at lower MOIs (MOI of 0.25; 65%
viral E protein cells) downstream of type I IFN signaling in Vero cells. ZIKV infection at 
the higher MOI of 1 showed levels of STAT5 antagonism similar to those observed in 
human moDCs (Fig. 4C and D). Consistent with recent work on STAT antagonism by 
ZIKV, we also observed diminished STAT1 phosphorylation, as well as decreased STAT2 
phosphorylation that corresponded with degradation of STAT2 total protein (10, 16). In 
contrast to WNV at similar infection levels (percentage of viral E protein cells: DENV1, 
53.9%; DENV2, 64%; DENV3, 60.5%; DENV4, 55.7%; YFV-17D, 51.7%), STAT5 phosphor-
ylation was not blocked in Vero cells infected with DENV1 to DENV4 and YFV-17D 
following IFN- pulse treatment (Fig. 5A to F). Consistent with previous studies of
FIG 4 WNV and ZIKV antagonize STAT5 phosphorylation in the absence of IFN signaling. (A) Vero cells were 
infected with WNV-TX (MOI of 0.01, based on Vero cell titer) or ZIKV-PRVABC59 (MOI of 0.25 or 1, based on Vero 
cell titer), and the percentage of E protein cells was determined by flow cytometry at 24 hpi. (B) Vero cells were 
left uninfected (Mock) or infected with WNV-TX (MOI of 0.01, based on Vero cell titer) at 24 hpi. (C and D) Vero cells 
were left uninfected (Mock) or infected with ZIKV (MOI of 0.25 or 1, based on Vero cell titer) at 24 hpi. Data are 
representative of results obtained from three independent experiments.
DENV2 antagonism of type I IFN signaling (17), we observed STAT2 degradation in Vero
cells infected with DENV1, -2, and -4, while STAT1 phosphorylation was detected after
IFN- pulse treatment. Markedly, DENV3 did not show degradation of STAT2 but 
showed a slight reduction in STAT2 phosphorylation, suggesting that antagonism of
STAT2 by DENV may have a serotype-specific effect in Vero cells. Altogether, these 
findings demonstrate that antagonism of STAT5 is a virus-specific strategy used by WNV
and ZIKV to potentially subvert the antiviral landscape in human DCs during infection.
ZIKV, but not WNV, blocks activation of TYK2 and JAK1. The pathway-specific 
inhibition of STAT5 through type I IFN and IL-4 signaling, but not GM-CSF signaling, 
within moDCs provides insight into the host target of viral antagonism. The type I IFN 
receptor and the type II IL-4 receptor associate with JAK1 and TYK2 to mediate tyrosine 
phosphorylation of STAT1 and STAT2, while TYK2 constitutively associates with STAT5
and mediates its tyrosine phosphorylation (28, 29). GM-CSF signaling through the
GM-CSF receptor predominately activates JAK2, but not JAK1 or TYK2, suggesting that
TYK2 and JAK1 may be targeted to block STAT5 phosphorylation (30, 31). To assess JAK 
inhibition, we infected Vero cells at an MOI of 0.1 with WNV for 12, 18, and 24 h. 
Consistent with the lack of endogenous type I IFN production, WNV infection alone did
not induce TYK2 phosphorylation. Although we did observe JAK1 phosphorylation, this
is likely explained by the production of other cytokines that can activate JAK1 (32). In 
contrast to blockade of STAT protein phosphorylation, we observed no blockade of
TYK2 and enhanced JAK1 phosphorylation following IFN- pulse treatment of infected
FIG 5 DENV1 to DENV4 and YFV-17D do not antagonize STAT5 phosphorylation at infection levels similar to those of WNV.
(A) Vero cells were infected with DENV1 to DENV4 or YFV-17D (MOI of 1, based on Vero cell titer), and the percentages of
E protein cells were determined by flow cytometry at 24 hpi. Vero cells were left uninfected (Mock) or infected with
YFV-17D (MOI of 0.1 or 1, based on Vero cell titer) (B) or with DENV1 to DENV4 (MOI of 0.1 or 1, based on Vero cell titer)
for 24 h (C to F). Cells were then left untreated or pulse treated with IFN- (1,000 IU/ml) for 30 min. For data shown in
panels B to F, Western blot analysis was performed for the indicated proteins. Data are representative of results obtained
from two independent experiments.
cells (Fig. 6A). Despite its similarities to WNV in inhibiting STAT5 phosphorylation, ZIKV 
efficiently blocked phosphorylation of both JAK1 and TYK2 downstream of type I IFN 
signaling (Fig. 6B). Previous work has shown that flaviviruses are capable of downregu-
lating IFNAR1 from the cell surface (33, 34), so, we assessed whether ZIKV infection 
decreased expression of IFNAR1 or IFNAR2 from the Vero cell surface (Fig. 6C). Although 
at 24 hpi we observed blockade of JAK1 and TYK2 phosphorylation in ZIKV-infected 
Vero cells, we also observed an increase in both IFNAR1 and IFNAR2 expression 
compared to that in mock-infected cells. Combined, these findings suggest that WNV 
and ZIKV antagonize STAT5 signaling through two separate mechanisms: ZIKV at the 
level of JAK kinase phosphorylation and WNV downstream of JAK kinases, potentially 
through more direct inhibition of STAT5 phosphorylation.
DISCUSSION
In this study, we combined traditional virologic and immunologic measures with 
transcriptomic and computational approaches to define the global antiviral response 
during WNV infection in human primary cells. Using cis-regulatory sequence analysis, 
STAT5, a transcription factor previously described as a regulator of DC activation, was 
identified as an important regulatory node of antiviral DC responses downstream of 
innate immune signaling. In contrast, STAT5 signaling was minimally activated during 
WNV infection in human moDCs, corresponding with minimal expression of genes of 
inflammatory responses or molecules involved in T cell priming. Mechanistically, WNV 
and ZIKV blocked STAT5 phosphorylation downstream of RIG-I, IFN-, and IL-4, but not 
GM-CSF, signaling, suggesting pathway-specific antagonism of STAT5 activation in
FIG 6 ZIKV, but not WNV, blocks TYK2 and JAK1 activation to compromise STAT5 phosphorylation. (A 
and B) Vero cells were left uninfected (Mock) or infected with WNV (MOI of 0.1, based on Vero cell titer) 
or ZIKV-PRVABC59 (MOI of 1, based on Vero cell titer) for 24 h. Cells were then either left untreated or 
pulse treated with IFN- (1,000 IU/ml) for 30 min. (C) Vero cells were left uninfected (Mock) or infected 
with WNV (MOI of 1, based on Vero cell titer) for 24 h, and levels of surface IFNAR1 and IFNAR2 expression 
were measured by flow cytometry. For panels A and B, Western blot analysis was performed for the 
indicated proteins. Data in A and B are representative of results obtained from two independent 
experiments.
moDCs. Notably, neither the related flaviviruses DENV1 to DENV4 nor the vaccine strain 
YFV-17D inhibited STAT5 phosphorylation. Mechanistically, WNV and ZIKV displayed 
differential inhibition of JAK1 and TYK2 phosphorylation, indicating two distinct mech-
anisms to antagonize STAT5 signaling. Combined, our data identify antagonism of 
STAT5 phosphorylation as a conserved immune countermeasure used by certain 
pathogenic flaviviruses.
cis-Regulatory sequence analysis revealed STAT5 as a regulatory node of multiple 
components of DC activation downstream of RLR and type I IFN signaling. Indeed, we 
observed significant enrichment for multiple STAT5 target genes involved in DC 
activation, which corresponded with increased gene expression and secretion of pro-
inflammatory cytokines and upregulation of proteins involved in T cell activation (11). 
While this confirms previous studies that have implicated STAT5 upstream of DC 
activation, our work reveals a new facet of STAT5 activation during flavivirus infection 
through engagement of innate immune signaling (21, 22). The rapid kinetics of STAT5 
phosphorylation following RIG-I or MDA5 stimulation suggest that RLR signaling may 
directly induce phosphorylation of STAT5 through activation of a tyrosine kinase, such 
as Src or Lyn, both of which are induced by RLR signaling (35–39). Alternatively, rapid 
production of type I IFN, which also promotes STAT5 activation, may mediate STAT5 
phosphorylation following RLR signaling. Combined, our data suggest that STAT5 is an 
important regulatory node downstream of the RLR and type I IFN signaling axis.
In contrast to RLR and IFN- signaling, WNV infection did not upregulate most 
predicted STAT5 target genes, and STAT5 was not phosphorylated during infection 
despite secretion of IFN- and IFN-. Corresponding with minimal STAT5 enrichment, 
WNV infection failed to promote upregulation of inflammatory mediators and mole-
cules involved in antigen presentation and T cell cosignaling. These findings are similar 
to those of previous work, in which WNV infection also failed to induce inflammatory 
cytokine secretion (40). Infection of moDCs with a nonpathogenic WNV isolate, WNV 
Kunjin, also induced minimal production of IL-12, despite notable upregulation of both 
CD86 and CD40 (41). This suggests that an inability to induce inflammatory cytokine
responses may be shared among WNV strains, while pathogenic strains have evolved 
unique mechanisms to subvert antigen presentation and T cell activation. The lack of 
activation of WNV-infected human moDCs is also similar to our recent work with ZIKV 
(10). In contrast to WNV and ZIKV, infection of moDCs with the YFV vaccine strain 
(YFV-17D) upregulates multiple inflammatory mediators and surface expression of 
CD80 and CD86 (42). The ability of YFV-17D to induce strong DC activation may reflect 
the loss of viral antagonism during the attenuation process, similar to the ability of WNV 
Kunjin to induce upregulation of CD86 and CD40 (41). Alternatively, the ability of 
YFV-17D to induce DC activation may be an inherent property of certain flaviviruses. 
Indeed, DENV has also been found to activate inflammatory responses and upregulate 
costimulatory molecules following infection despite its ability to degrade STAT2 in 
infected cells (17, 43, 44). We demonstrate here that, unlike WNV and ZIKV, YFV-17D 
and DENV1 to DENV4 do not inhibit STAT5 phosphorylation in Vero cells. This raises the 
possibility that the inability to block STAT5 may explain the activation induced during 
YFV-17D and DENV infection. Altogether, we demonstrate that WNV, similar to ZIKV, 
induces minimal DC activation during productive infection, contrasting with both DENV 
and YFV-17D.
Blockade of STAT5 signaling by WNV was found to be multifrontal, as multiple 
STAT5-signaling cytokines induced downstream of RIG-I signaling (GM-CSF, IL-4, and 
IL-15) are not produced during infection with WNV (11). The lack of GM-CSF secretion 
may also overcome the need for WNV to block GM-CSF-induced STAT5 phosphoryla-
tion. Similar to WNV, ZIKV has also been found to induce minimal secretion of cytokines, 
including IL-4, GM-CSF, IL-12, IL-15, and RANTES, during infection of human moDCs (10). 
In contrast, DENV and YFV-17D infection in human moDCs has been reported to induce 
proinflammatory cytokine expression and secretion, including IL-12 and RANTES (45–
48). This robust cytokine response could potentially reflect the inability of DENV and 
YFV-17D to inhibit STAT5-signaling cytokines. Combined, these findings suggest that 
the ability to antagonize STAT5 signaling may be an important feature of WNV and ZIKV 
pathogenesis.
Surprisingly, viral blockade of STAT5 phosphorylation during WNV infection, but not 
ZIKV infection, did not correspond with impaired activation of TYK2 and JAK1, members 
of the Janus-associated kinase (JAK) family that phosphorylate STAT5 downstream of 
type I IFN and IL-4, but not GM-CSF, signaling. Numerous flaviviruses, including the 
closely related Japanese encephalitis virus (JEV) and Langat virus, have been shown to 
inhibit TYK2 activation through the NS5 protein to subvert JAK/STAT signaling (18, 49). 
Nevertheless, our work suggests that inhibition of TYK2 or JAK1 activation is likely not 
the mechanism used by WNV to block STAT5 phosphorylation. Indeed, STAT1 and 
STAT2, which are also phosphorylated by TYK2 and JAK1, were not blocked as strongly 
as STAT5, suggesting that viral inhibition may be occurring at a step unique to STAT5 
signaling. STAT5 itself is likely not targeted directly, given that GM-CSF-induced STAT5 
signaling remains intact during WNV infection. One possibility is that WNV may 
specifically disrupt the interaction between STAT5 and TYK2 or JAK1. WNV infection 
may also directly induce negative regulators of STAT5 signaling, such as facilitating 
interactions between STAT5 and the protein tyrosine phosphatase, SHP-2, a well-known 
regulator of cytosolic STAT5 signaling (50). Another possibility includes induction of the 
suppressor of cytokine signaling family, members of which broadly regulate JAK/STAT 
signaling and can be modulated during flavivirus infection (51). Importantly, UV-
inactivated virus, which undergoes cellular binding and entry but is replication incom-
petent, was unable to inhibit STAT5. This suggests that viral replication is required for 
STAT5 antagonism, potentially through a secreted viral protein that would affect both 
infected and uninfected cells. The observation that DENV1 to DENV4 and YFV-17D do 
not block STAT5 phosphorylation provides a valuable tool to further define the viral and 
host factors within subsets of flaviviruses that mediate STAT5 blockade.
In summary, our systems biology approach identified STAT5 as a regulator of DC 
activation that is blocked by WNV as a mechanism to subvert DC activation and T cell 
priming. ZIKV, but not YFV-17D or DENV1 to DENV4, also blocked STAT5 signaling,
suggesting that viral antagonism of STAT5 may be a common strategy of particular
subsets of pathogenic flaviviruses to evade the pressures of host immunity. Our study
advances our understanding of how pathogenic flaviviruses subvert antiviral immunity
during human infection.
MATERIALS AND METHODS
Ethics statement. Human peripheral blood mononuclear cells (PBMCs) were obtained from deiden-
tified healthy adult blood donors and processed immediately. All individuals who participated in this 
study provided informed consent in writing in accordance to the protocol approved by the Institutional 
Review Board of Emory University (IRB no. 00045821), entitled “Phlebotomy of healthy adults for the 
purpose of evaluation and validation of immune response assays.”
Cell lines. Vero cells (WHO Reference Cell Banks) were maintained in complete Dulbecco’s modified 
Eagle’s medium (DMEM). Complete DMEM was prepared as follows: DMEM (Corning) supplemented with 
10% fetal bovine serum (Optima, Atlanta Biologics), 2 mM L-glutamine (Corning), 1 mM HEPES (Corning), 
1 mM sodium pyruvate (Corning), 1 minimal essential medium (MEM) nonessential amino acids 
(Corning), and 1 antibiotics/antimycotics (Corning). Complete RPMI (cRPMI) medium was prepared as 
follows: RPMI 1640 medium (Corning) supplemented with 10% fetal bovine serum (Optima, Atlanta 
Biologics), 2 mM L-glutamine (Corning), 1 mM sodium pyruvate (Corning), 1 MEM nonessential amino 
acids (Corning), and 1 antibiotics/antimycotics (Corning).
Generation of monocyte-derived dendritic cells. To generate human moDCs, CD14 monocytes 
were differentiated in cRPMI medium supplemented with 100 ng/ml GM-CSF and IL-4 for 5 to 6 days, as 
previously described (10). In brief, freshly isolated PBMCs obtained from healthy donor peripheral blood 
(lymphocyte separation medium; StemCell Technologies) were subjected to CD14 magnetic bead 
positive selection using a MojoSort human CD14 selection kit (BioLegend). Purified CD14 monocytes 
were cultured in complete RPMI medium supplemented with 100 ng/ml each of recombinant human IL-4 
and GM-CSF (PeproTech) at a cell density of 2e6 cells/ml. After 24 h of culture, medium and nonadherent 
cells were removed and replaced with fresh medium and cytokines. Suspension cells (moDCs) were 
harvested after 5 to 6 days of culture and were consistently CD14 CD11c HLA-DR DC-SIGN CD1a 
by flow cytometry. For experimentation, moDCs were maintained in complete RPMI medium without 
GM-CSF or IL-4. For experiments measuring STAT5 phosphorylation, moDCs were rested in cRPMI 
medium without GM-CSF or IL-4 for 24 h prior to experimentation.
Viruses. WNV stocks were generated from an infectious clone, WNV isolate TX 2002-HC, and 
passaged once in Vero cells, as previously described (52). ZIKV strain PRVABC59 was obtained from the 
Centers for Disease Control and Prevention as previously described (53). YFV-17D was subpassaged from 
YF-VAX (Aventis Pasteur) in SW-480 cells, followed by passaging in Vero cells as previously described (42). 
The DENV1, DENV3, and DENV4 strains were derived from low-passage-number clinical isolates and 
generated from infectious clones (IC) as previously described (54–56). The DENV2 IC was generated in the 
laboratory of R. S. Baric in a similar manner to the DENV1, DENV3, and DENV4 IC. The generation and 
characterization of the DENV2 S16803 IC will be described in a future publication. WNV and ZIKV were 
titrated by plaque assay on Vero cells with a 1% agarose overlay and crystal violet counterstain, as 
previously described (52). DENV was titrated by focus-forming assay as previously described (56). moDCs 
were infected with WNV or ZIKV at an MOI of 10 for 1 h at 37°C in cRPMI medium (without GM-CSF or 
IL-4). After 1 h, virus was washed off, and cells were resuspended in fresh cRPMI medium and incubated 
at 37°C for 3 to 72 h.
Quantitation of infectious virus. Infectious virus was quantitated using a plaque assay on Vero cells 
with a 1% agarose overlay and crystal violet counterstain, as previously described (52).
Innate immune agonists. To stimulate RIG-I signaling, 100 ng of RIG-I agonist derived from the 3= 
untranslated region (UTR) of hepatitis C virus (57) was transfected per 1e6 cells using a TransIT-mRNA 
transfection kit (Mirus). For stimulation of MDA5 signaling, 100 ng of high-molecular-weight poly(I·C) was 
transfected per 1e6 cells using LyoVec transfection reagent (Invivogen). To stimulate type I IFN signaling, 
cells were incubated with 100 IU/ml of human recombinant IFN-. In select experiments, different doses 
of agonists were used, and this is indicated within the respective figure legends.
RNA sequencing and bioinformatics. moDCs were generated from 5 donors and either treated with 
innate immune agonists for 12 h (RIG-I, MDA5, or IFN-) or infected with WNV (12 hpi and 24 hpi). Total 
RNA was purified (Quick-RNA MiniPrep kit; Zymo Research), and mRNA sequencing libraries were 
prepared for RNA sequencing (TruSeq chemistry; Illumina). RNA sequencing was performed on an 
Illumina HiSeq 2500 System (100-bp single-end reads). Sequencing reads were mapped to the human 
reference genome 38. Weighted gene coexpression module analysis was performed on DESeq2 normal-
ized mapped reads (TIBCO Spotfire with Integromics, version 7.0) from RIG-I agonist-, MDA5 agonist-, 
IFN--, and mock-treated samples. First, the data sets were reduced to focus the network analysis on the 
5,446 most variable genes (as determined by variation value greater than 1) using the variance function 
in R. We constructed a signed weighted correlation network by generating a matrix pairwise correlation 
between all annotated gene pairs. The resulting biweight midcorrelation matrix was transformed into an 
adjacency matrix using the soft thresholding power (1) of 12. The adjacency matrix was used to define 
the topological overlap matrix (TOM) based on a dissimilarity measurement of 1  TOM. Genes were 
hierarchically clustered using average linkage, and modules were assigned using the dynamic tree-
cutting algorithm (module eigengenes were merged if the pairwise calculation was larger than 0.75). This 
resulted in the construction of six modules. Transcriptional regulators within the M5 module were 
computationally predicted with iRegulon (24), using the top most connected M5 genes using an
TABLE 1 Primary antibodies used in this study
Primary antibodya Source or reference Catalog no.
Rabbit anti-human phospho-STAT1 (Tyr701, clone D4A7) Cell Signaling Technologies 7649
Rabbit anti-human STAT1 (clone 9172) Cell Signaling Technologies 9172
Rabbit anti-human phospho-STAT2 (Tyr689, Upstate) EMD Millipore 07-224
Rabbit anti-human STAT2 (clone D9J7L) Cell Signaling Technologies 72604
Rabbit anti-human phospho-STAT5 (Tyr694, clone D47E7) Cell Signaling Technologies 4322
Rabbit anti-human STAT5 (clone 9363) Cell Signaling Technologies 9363
Rabbit anti-human phospho-IRF3 (Ser396, clone 4D4G) Cell Signaling Technologies 4947
Rabbit anti-human total IRF3 (clone D83B9) Cell Signaling Technologies 4302
Rabbit anti-human total Tyk2 (clone D4I5T) Cell Signaling Technologies 14193
Rabbit anti-human phospho-Tyk2 (Tyr1054/1055, clone D7T8A) Cell Signaling Technologies 68790
Rabbit anti-human total JAK1 (clone 6G4) Cell Signaling Technologies 3344
Rabbit anti-human phospho-JAK1 (Tyr1034/1035, clone D7N4Z) Cell Signaling Technologies 74129
Rabbit anti-human GAPDH (clone D16H11) Cell Signaling Technologies 5174
Mouse anti-human CD11c (BV710, clone B-Ly6) BD Biosciences 563130
Mouse anti-human HLA-DR (PE-CF594, clone G46-6) BD Biosciences 562304
Mouse anti-human CD1a (BV421, clone HI149) BioLegend 300128
Mouse anti-human CD14 (PE, clone M5E2) BioLegend 301806
Unconjugated monoclonal humanized E16 antibody 58
Unconjugated monoclonal mouse 4G2 antibody 53
aGAPDH, glyceraldehyde-3-phosphate dehydrogenase; PE, phycoerythrin.
eigengene-based connectivity cutoff of 0.4. Differentially expressed genes within the M5 module were 
identified as having a 2-fold change (significance at a P value of 0.01) relative to levels in uninfected 
and untreated cells. Pathway analysis was performed on M5 genes using MetaCore pathway map analysis 
(version 6.29; Thomson Reuters).
Flow cytometry. Cells were prepared for analysis as previously described (10). For intracellular 
staining of WNV E protein, human moDCs and Vero cells were fixed and permeabilized (Transcription 
Factor Staining Buffer kit; Tonbo Biosciences). The cells were reblocked for 5 min on ice with 0.25 l/
sample human TruStain FcX and 0.25 l/sample normal mouse serum (ThermoFisher Scientific) in Perm 
Buffer and E protein for 20 min on ice using 0.5 l/sample of allophycocyanin-labeled E16 (E16-APC) (for 
WNV) (58) or the pan-flavivirus 4G2-APC antibody (for ZIKV, DENV1 to DENV4, and YFV-17D) in Perm 
Buffer. Unconjugated monoclonal 4G2 antibody was conjugated to APC using a Novus Lighting-Link kit 
per the manufacturer’s instructions. Flow cytometry data were analyzed using FlowJo, version 10, 
software. Primary antibodies are listed in Table 1.
Western blotting. Whole-cell lysates were collected in modified radioimmunoprecipitation assay 
buffer (10 mM Tris [pH 7.5], 150 mM NaCl, 1% sodium deoxycholate, and 1% Triton X-100 supplemented 
with Halt protease inhibitor cocktail [ThermoFisher] and Halt phosphatase inhibitor cocktail [Thermo-
Fisher]). Protein lysates were separated by SDS-PAGE, and Western blotting was performed using a 
ChemiDoc XRS imaging system (Bio-Rad). Western blots were analyzed using Image Lab, version 5.2.1, 
software (Bio-Rad) and prepared for publication using Adobe Illustrator. Primary antibodies are listed in 
Table 1.
Statistics. All statistical analysis was performed using GraphPad Prism, version 8, software. The 
number of donors varied by experiment and is indicated within the figure legends. Statistical significance 
was determined at a P value of 0.05 using a Kruskal-Wallis test (when more than two groups lacking 
paired measurements were compared) and a Wilcoxon test (when two groups with paired measurements 
were compared). All comparisons were made between treatment or infection conditions with a time 
point-matched, uninfected and untreated control.
Data availability. The raw data of all RNA sequencing in this publication have been deposited in 
NCBI’s Gene Expression Omnibus (GEO) under GEO accession number GSE136342.
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